3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
41
Stomach Neoplasms
3
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Positive Breast Cancer
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Cyclophosphamide
13
Doxorubicin
9
Trastuzumab
8
Taxes
7
Paclitaxel
7
Docetaxel
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
Radiotherapy
4
Epirubicin
4
pertuzumab
3
pembrolizumab
3
Melphalan
3
130-nm albumin-bound paclitaxel
3
eribulin
2
Thiotepa
2
Tamoxifen
2
Peripheral Blood Stem Cell Transplantation
2
Lapatinib
2
Fluorouracil
2
Filgrastim
2
Bevacizumab
2
2C4 antibody
2
trastuzumab biosimilar HLX02
1
talimogene laherparepvec
1
sargramostim
1
ruxolitinib
1
romidepsin
1
pegfilgrastim
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Inflammatory Breast Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts